Article
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
JAMA oncology - 1 Jul 2017
Heinrich Michael C, Rankin Cathryn, Blanke Charles D, Demetri George D, Borden Ernest C, Ryan Christopher W, von Mehren Margaret, Blackstein Martin E, Priebat Dennis A, Tap William D, Maki Robert G, Corless Christopher L, Fletcher Jonathan A, Owzar Kouros, Crowley John J, Benjamin Robert S, Baker Laurence H
Abstract excerpt
IMPORTANCE: After identification of activating mutations of the KIT gene in gastrointestinal stromal tumor (GIST)-the most common sarcomaof the gastrointestinal tract-a phase 2 study demonstrated efficacy of imatinib mesylate in patients with metastatic GIST harboring a KIT exon 11 mutation. Initial results of long-term follow-up have found a survival benefit in this subgroup of patients. OBECTIVE: To assess the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.